Press Releases

August 10, 2026
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read More
PDF Version
August 6, 2026
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read More
PDF Version
July 9, 2026
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
Read More
PDF Version
June 3, 2026
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
Read More
PDF Version
June 1, 2026
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Read More
PDF Version